Is Futu’s bull run nearing an end?
The brokerage’s stock has more than doubled since the start of the year, as it records strong revenue and profit growth fueled by heavy trading volumes Key Takeaways: Futu reported…
China’s changing tastes buffet western brands as Ant Group faces old headwinds
Burger King withdraws from Hong Kong and Ant Group's purchase of a Hong Kong brokerage is getting extra scrutiny.
Mainland regulators trip up Ant Group – again
Hong Kong’s Bright Smart Securities says its plan to be acquired by Ant is progressing on schedule, but a media report suggests the deal may face greater regulatory scrutiny Key…
Will new investor Goldstream bring its Midas touch to Saint Bella?
The investment company disclosed its purchase of 0.3% of the maternity and baby care company’s stock on the open market Key Takeaways: Goldstream Investment acquired 1.83 million Saint Bella shares,…
Huishang Bank’s double-speak: Talking up profits, while highlighting challenges
The regional lender’s net profit increased 3.8% in the first half of 2025, far less than its asset expansion, suggesting intense margin pressure Key Takeaways: Huishang Bank’s total assets increased…
China’s new investment playbook: VCs chase crypto as a travel upstart eyes New York
Chinese venture capital firms are embracing cryptocurrencies. And up-and-coming online travel agent Klook is eying a major New York IPO.
Lufax deepens Ping An reliance, as it works towards trading resumption
The online loan facilitator has signed a flurry of agreements strengthening its ties to its parent, Ping An Group, as it works towards reinstatement of trading for its Hong Kong…
Recent Articles
RELATED ARTICLES
-
UP Fintech gets lift from tariff-induced market volatility
TIGR.US -
BRIEF: Futu profit doubles on heavy trading during stock market rally
FUTU.US
-
BRIEF: Futu’s profit doubles on stock market rebound
FUTU.US
-
Soaring stock brokers, and rising tobacco
FUTU.US TIGR.US
-
Red Bull slayer Eastroc chases Hong Kong IPO to boost global charge
605499.SHG
-
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
9939.HK
